2 Stocks for Bulls This Year: Beam Therapeutics, Bloom Energy

Beam Therapeutics (BEAM)Gene editing firm Beam Therapeutics is developing its own pipeline with base editing asits foundation technology, a technique that changes a single DNA or RNA base withoutcutting the DNA strand. The company ended the second quarter with $1 billion in cash,with an expected operating runway into 2027.Beam recently received new drug clearance for its first in-vivo regulatory filing, which is a way to make genetic modifications via nanoparticles injected into the body, as opposed to ex-v ...